steatohepatitis (NASH), raising the risk of cirrhosis and liver cancer. A challenge for doctors is identifying which NAFLD patients will go on to develop NASH and, for those with NASH, predicting how fast the disease will progress. LITMUS aims to deliver simple biological markers (e.g. from blood tests or imaging) that could be used to diagnose NASH and predict which patients will rapidly develop more serious liver disease.
LITMUS is a 34 million Euro project funded by the European Innovative Medicines Initiative (IMI) 2 Joint Undertaking. It is coordinated by Newcastle University and includes 47 international research partners, leading academic scientists as well as some of the world’s largest pharma companies. As one of the partners, Antaros Medical is responsible for advanced imaging including magnetic resonance elastography (MRE) and diffusion that will be carried out in nine European centers. MRE obtains information about the stiffness of tissue by assessing the propagation of mechanical waves through the tissue with a special magnetic resonance imaging technique. Diffusion is a way of measuring inflammation in the liver.
Non-alcoholic fatty liver disease (NAFLD) occurs when fat builds up in the liver. In some people, NAFLD turns into a more serious condition called non-alcoholic steatohepatitis (NASH), raising the risk of cirrhosis and liver cancer. NAFLD is quite common, affecting some 30% of the population, and a challenge for doctors is identifying which NAFLD patients will go on to develop NASH and, for those with NASH, predicting how fast the disease will progress. LITMUS aims to deliver simple biological markers (e.g. from blood tests or imaging) that could be used to diagnose NASH and predict which patients will rapidly develop more serious liver disease. It should also support non-invasive biomarkers with high reproducibility for drug development for treatment of NASH.
More information about LITMUS>>
Read the article>>